Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report
Lantern Pharma Inc. (LTRN)
Company Research
Source: Business Wire
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern” or the “Company”), an AI-driven, clinical-stage oncology company leveraging its proprietary RADR® platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on an unverified third-party website.The third-party article incorrectly claimed that Panna Sharma has stepped down as President and Chief Executive Officer of Lantern. This claim is false, entirely without basis, and appears designed to mislead investors. No such communication has been issued by the Company or its Board of Directors.Mr. Sharma continues to serve as President, Chief Executive Officer, and a Director of Lantern, and remains fully engaged in leading the Company’s strategy, operations, and portfolio of AI-driven oncology programs. He has no intention to step down from his roles with Lantern and he has not been requested to do so. As previously a
Show less
Read more
Impact Snapshot
Event Time:
LTRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LTRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LTRN alerts
High impacting Lantern Pharma Inc. news events
Weekly update
A roundup of the hottest topics
LTRN
News
- Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001Business Wire
- Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ETBusiness Wire
- RedChip Highlights Public Companies Advancing the Next Phase of AI Adoption at Virtual Investor Conference on March 19 [Yahoo! Finance]Yahoo! Finance
- Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition [Yahoo! Finance]Yahoo! Finance
- Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026Business Wire
LTRN
Earnings
- 8/13/25 - Beat
LTRN
Sec Filings
- 2/23/26 - Form SCHEDULE
- 1/23/26 - Form 8-K
- 1/13/26 - Form 4
- LTRN's page on the SEC website